Frontiers
US$ 25.19
glp-1 receptor agonist long term side effects Comparative safety and of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management Clinical Recommendations to Manage Gastrointestinal
Description
Antioxid (Basel) (2021) 10:1175
Moreover, the comparison between DPP-4 inhibitors and placebo demonstrated no difference in their risk for MACE (RR = 0.99, 95% CI 0.931.06)
Comprehensive metabolic health monitoring ensures safety
"Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review"
In 2024, a study led by Dr
We also manually searched the websites of the EASD and ADA scientific meetings, and ClinicalTrials.gov to retrieve either additional eligible trials or any additional information for trials already identified through the database searches
